{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:59:15Z","timestamp":1793228355342,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5 R01 HL126903-02"],"award-info":[{"award-number":["5 R01 HL126903-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5I01CX000829-04"],"award-info":[{"award-number":["5I01CX000829-04"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.kint.2017.08.038","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T08:59:40Z","timestamp":1513846780000},"page":"325-334","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Revisiting RAAS blockade in CKD with newer potassium-binding drugs"],"prefix":"10.1016","volume":"93","author":[{"given":"Panagiotis I.","family":"Georgianos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5 suppl 2","key":"10.1016\/j.kint.2017.08.038_bib1","first-page":"1","article-title":"K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease","volume":"43","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.08.038_bib2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kint.2017.08.038_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ki.2013.355","article-title":"Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?","volume":"85","author":"Sarafidis","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2017.08.038_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/ki.2012.425","article-title":"Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?","volume":"83","author":"Wheeler","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2017.08.038_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1053\/j.ajkd.2006.10.014","article-title":"Antihypertensive therapy in the presence of proteinuria","volume":"49","author":"Sarafidis","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.08.038_bib6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kint.2017.08.038_bib7","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2215\/CJN.07821109","article-title":"Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors","volume":"5","author":"Weir","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.08.038_bib8","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.08.038_bib9","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.08.038_bib10","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.kint.2017.08.038_bib11","article-title":"Current and future potassium binders","volume":"30","author":"Bakris","year":"2016","journal-title":"Nephrol News Issues"},{"key":"10.1016\/j.kint.2017.08.038_bib12","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1517\/14656566.2015.1083977","article-title":"Advances in treatment of hyperkalemia in chronic kidney disease","volume":"16","author":"Sarafidis","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.kint.2017.08.038_bib13","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2017.08.038_bib14","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2017.08.038_bib15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.08.038_bib16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.08.038_bib17","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.08.038_bib18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.08.038_bib19","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2017.08.038_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00125-010-1922-6","article-title":"Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial","volume":"54","author":"Miao","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.kint.2017.08.038_bib21","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/archinternmed.2009.284","article-title":"Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy","volume":"169","author":"Weinberg","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.kint.2017.08.038_bib22","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.kint.2016.09.010","article-title":"Management of patients with diabetes and CKD: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"90","author":"Perkovic","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2017.08.038_bib23","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.08.038_bib24","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.kint.2017.08.038_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11906-016-0649-2","article-title":"Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?","volume":"18","author":"Haller","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.kint.2017.08.038_bib26","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2017.08.038_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","article-title":"Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry?","volume":"158","author":"Reardon","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.kint.2017.08.038_bib28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/pds.1923","article-title":"Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril","volume":"19","author":"Johnson","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.kint.2017.08.038_bib29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2017.08.038_bib30","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.kint.2017.08.038_bib31","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2215\/CJN.05850809","article-title":"Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study","volume":"5","author":"Korgaonkar","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.08.038_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.01730215","article-title":"Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function","volume":"11","author":"Luo","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.08.038_bib33","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000437151","article-title":"Serum Potassium, End-Stage Renal Disease and Mortality in Chronic Kidney Disease","volume":"41","author":"Nakhoul","year":"2015","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2017.08.038_bib34","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.ajkd.2017.01.044","article-title":"Race, Serum Potassium, and Associations With ESRD and Mortality","volume":"70","author":"Chen","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.08.038_bib35","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/HYPERTENSIONAHA.116.07363","article-title":"Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System","volume":"67","author":"Chang","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.kint.2017.08.038_bib36","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1681\/ASN.2010010079","article-title":"Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective?","volume":"21","author":"Sterns","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.08.038_bib37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM196101192640303","article-title":"Management of hyperkalemia with a cation-exchange resin","volume":"264","author":"Scherr","year":"1961","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.08.038_bib38","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2215\/CJN.03640415","article-title":"Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD","volume":"10","author":"Lepage","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2017.08.038_bib39","doi-asserted-by":"crossref","first-page":"264.e9","DOI":"10.1016\/j.amjmed.2012.08.016","article-title":"Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review","volume":"126","author":"Harel","year":"2013","journal-title":"Am J Med"},{"key":"10.1016\/j.kint.2017.08.038_bib40","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/SMJ.0b013e31819e8978","article-title":"Intestinal necrosis due to sodium polystyrene sulfonate (Kayexalate) in sorbitol","volume":"102","author":"McGowan","year":"2009","journal-title":"South Med J"},{"key":"10.1016\/j.kint.2017.08.038_bib41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1053\/j.ajkd.2012.04.023","article-title":"Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study","volume":"60","author":"Watson","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2017.08.038_bib42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1056\/NEJMe1414112","article-title":"A\u00a0new era for the treatment of hyperkalemia?","volume":"372","author":"Ingelfinger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.08.038_bib43","first-page":"1571","article-title":"New agents for hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.08.038_bib44","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/14656566.2016.1190333","article-title":"Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer","volume":"17","author":"Epstein","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.kint.2017.08.038_bib45","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1177\/1074248417691135","article-title":"Evaluation of the potential for drug interactions with patiromer in healthy volunteers","volume":"22","author":"Lesko","year":"2017","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.kint.2017.08.038_bib46","doi-asserted-by":"crossref","first-page":"e114686","DOI":"10.1371\/journal.pone.0114686","article-title":"Characterization of structure and function of ZS-9, a K+ selective ion trap","volume":"9","author":"Stavros","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2017.08.038_bib47","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.kint.2017.08.038_bib48","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.08.038_bib49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2017.08.038_bib50","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2017.08.038_bib51","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2014.15688","article-title":"Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial","volume":"312","author":"Kosiborod","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2017.08.038_bib52","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/ejhf.402","article-title":"Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors","volume":"17","author":"Pitt","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.kint.2017.08.038_bib53","unstructured":"Relypsa, Inc. NCT03071263: Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease (AMBER). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03071263?term=AMBER&rank=6. Accessed May 2,\u00a02017."},{"issue":"suppl 1","key":"10.1016\/j.kint.2017.08.038_bib54","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/HJH.0000000000001278","article-title":"Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics","volume":"35","author":"Weir","year":"2017","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.kint.2017.08.038_bib55","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000435842","article-title":"Adverse effects of conventional thrice-weekly hemodialysis: is it time to avoid 3-day interdialytic intervals?","volume":"41","author":"Georgianos","year":"2015","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2017.08.038_bib56","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1159\/000451067","article-title":"Patiromer Decreases Serum Potassium and Phosphate Levels in Patients on Hemodialysis","volume":"44","author":"Bushinsky","year":"2016","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2017.08.038_bib57","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/j.ajkd.2015.09.029","article-title":"New Potassium Binders: A Call to Test Their Efficacy and Safety in Dialysis Patients","volume":"67","author":"Georgianos","year":"2016","journal-title":"Am J Kidney Dis"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253817308086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253817308086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:49:18Z","timestamp":1758761358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253817308086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0085253817308086"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2017.08.038","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting RAAS blockade in CKD with newer potassium-binding drugs","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2017.08.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}